



BACTERIAL VAGINOSIS IS A DANGEROUS DISEASE

Asian International University

Temirova Dilnoza Olimjonovna

Bacterial vaginosis (BV) is a disorder of the vaginal microflora that occurs when the normal microbiota is replaced by high concentrations of anaerobic bacteria. Statistics from various authors show that 40–50% of all cases of the appearance or change of vaginal discharge are caused by bacterial vaginosis and approximately 25 to 50% of women today suffer from this disease [1–5].

The incidence of this disorder often depends on the population of women examined. It is 17–19% in family planning clinics and among female students observed in student clinics; 24–37% – among women undergoing treatment in sexually transmitted disease clinics; 20–25% – among pregnant women [6, 7]. The presence of this disease is observed in 30–50% of African American women, and in 10–20% of white women [8, 9].

Given the frequency of BV relapses, treatment and prevention of disease relapses are currently an important problem in pharmacotherapy. The ineffectiveness of antimicrobial drugs occurs due to the lack of a complete understanding of the pathogenesis of BV, as well as the causes of its relapses, which affects the effectiveness of treatment

This review examines the latest data on the pathogenesis of BV, treatment methods, and possible strategies to reduce disease relapses. Currently, new strategies to improve the effectiveness of disease treatment include changes in drug dose, treatment duration, long-term prophylactic regimens, and the use of biofilm disrupting agents. the use of high-dose suppositories containing metronidazole in combination with an antifungal agent, usually miconazole, which is also useful for mixed bacterial-fungal infections of the vagina. It is likely that future therapy will involve the simultaneous use of several components, including combinations of antibiotics, antibiofilm agents and probiotics.



Key words: bacterial vaginosis, vaginal microflora, treatment, metronidazole, clindomycin, suppositories.

The prevalence of BV varies by country and population, but a recent systematic review and meta-analysis estimated the global prevalence of BV among women of reproductive age to be 23–29%.

BV increases the risk of contracting HIV, as well as the acquisition and onward transmission of other STIs and, if untreated, can lead to adverse consequences in pregnancy

The main similarity between AB and BV is that in both conditions there is a significant decrease in the amount lactobacilli, leading to a decrease in the concentration of lactic acid and, accordingly, an increase in the pH of the vaginal environment, and their replacement by conditionally pathogenic microorganisms. The differences between these diseases are significant. BV is characterized by the absence of inflammation and the presence of a large amount of anaerobic microflora. Usually involved in the development of BV

Gardnerella vaginalis, *Atopobium vaginae*, *Prevotella* spp., *Porphyromonas* spp., *Bacteroides* spp., *Peptostreptococcus* spp., *Mobiluncus* spp., *Megasphaera* spp., *Leptotrichia* spp., *Dialister* spp., bacteria associated with bacterial vaginosis (bacterial vaginosis associated bacteria) BVAB1, BVAB2, BVAB3, belonging to the order Clostridiales. AB in its typical presentation is characterized by an increased inflammatory response and/or severe signs of atrophy of the vaginal epithelium and the presence of a moderate amount of commensal intestinal microflora

Most often, *Streptococcus* spp is detected in AV. (up to 59% of cases), *Staphylococcus aureus* (up to 42%), coagulase-negative staphylococci (up to 37%), *Escherichia coli* (up to 23%) [1]. BV is the most common disorder of the vaginal microecosystem in women of reproductive age. The prevalence of the disease varies extremely widely (7–68%) depending on region, ethnicity/race, and population studied [2].

Thus, among women with vaginal discharge, the incidence of BV is 20–30%, and among patients at high risk of sexually transmitted infections (STIs), it reaches



50–60% [3]. The main clinical manifestation of BV is specific discharge formed as a result of fermentation of normal vaginal mucin gel. Amines give the secretions a specific (“fishy”) odor.

At an alkaline pH, the non-volatile salts of these compounds are converted into volatile amines, and the “fishy” odor becomes noticeable or intensifies. Signs of vulvovaginitis are not typical for BV (unless it is accompanied by trichomoniasis or candidiasis). Many women with BV have no symptoms. Research in recent years shows that BV not only reduces a woman’s quality of life, but is also associated with a number of inflammatory diseases of the genitourinary tract, and is one of the common causes of pregnancy complications [4–7]. The disease often takes a relapsing form: 60% of women experience relapses of BV within 12 months after treatment [8]. The prevalence of AV among women of reproductive age, according to different authors, varies from 5 to 24% [1, 9, 10]. In a study by M. Jahic et al. (2013) AB frequency in women with signs of vaginitis was 51% [11]. In women with a normal pregnancy, AV was detected in 3–10% of cases [12–14]. The clinical picture of AB is similar to the clinical picture of trichomoniasis: profuse yellow or greenish-yellow discharge, burning and itching in the vagina and in the area of the vaginal vestibule, dyspareunia. During a gynecological examination, swelling, hyperemia, petechial rashes are noted, superficial erosions of the mucous membrane of the cervix, walls and vestibule of the vagina. As with trichomoniasis, the pH of vaginal discharge is elevated, but unlike trichomoniasis, in which the amine test is often positive, the amine test for AB gives a negative result. Symptoms may be present for a long time (months and sometimes years), with varying degrees of severity. Not uncommon cases when patients receive several courses of therapy for AV without visible results. Many women have microscopic signs of AV in the absence of symptoms, but the frequency of such asymptomatic forms of AV is unknown. The severe form of AV is very similar to desquamative inflammatory vaginitis, a clinical syndrome characterized by diffuse exudative inflammation, desquamation of parabasal epithelial cells, abundant purulent discharge, increased pH value of the vaginal

environment [15–17]. In 1994 J.D. Sobel retrospectively described 51 cases of this disease [17].

The results of the studies allow us to distinguish two variants of the clinical course of BV: asymptomatic and with clinical symptoms. It should be noted that the majority of women (50–75%) who are diagnosed with bacterial vaginosis have no symptoms of this condition at all. In this case, we talk about the so-called asymptomatic form of bacterial vaginosis. With an asymptomatic course, there are no clinical manifestations of the disease along with positive laboratory signs. Other patients with BV, as a rule, complain of copious white or gray discharge from the genital tract, often with a “fishy” o especially after unprotected intercourse or during menstruation. Seminal fluid has a pH of 7.0, so after ejaculation, the vaginal pH increases, as a result of which amines become free and cause an unpleasant odor. Thus, an increase in unpleasant odor after sexual intercourse serves as a definite differential diagnostic sign of BV.

The duration of these symptoms can be years. As the process progresses, the discharge acquires a yellowish-greenish color, becomes thicker, foamy, slightly viscous and sticky, and is evenly distributed over the walls of the vagina. The amount of leucorrhoea varies from moderate to very profuse. BV itself does not pose a threat to health, but prolonged and abundant

- vaginal discharge is accompanied by a significant decrease in a woman’s quality of life (sexual function is impaired, performance decreases, etc.).

- According to the recommendations of the Center for Disease Control (CDC), the treatment regimen for BV includes:

- • metronidazole orally 500 mg 2 times a day for 7 days;
- • clindamycin cream 2% – 1 full applicator (5 g) intravaginally at night for 7 days;

- • metronidazole gel 0.75% – 1 applicator (5 g) intravaginally at night for 5 days.

- The following are considered alternative treatment regimens:

- • metronidazole orally 2 g once;



- clindamycin orally 300 mg 2 times a day for 7 days;
- clindamycin 100 mg intravaginally at night for 3 days.
- According to the recommendations of the World Health Organization (WHO), the standard treatment for bacterial vaginosis is taking metronidazole 400 or 500 mg twice a day for 7 days or 2 g once. The European Association for STIs (IUSTI/WHO) also recommends metronidazole 400 or 500 mg twice a day for 7 days or 2 g once or clindamycin vaginal cream 2% 5 g at night for 7 days. According to 2010 Federal Guidance.

- (Formular system), for BV it is recommended:
 - clindamycin 2% 5 g 1 r/day (at night) intravenously (using a standard applicator) for 3 days;

- metronidazole po 0.5 g every 12 hours for 7 days;
- metronidazole IV 1 tablet. (0.5 g) at night, course 10 days;
- metronidazole gel 0.75% (5.0 g) at night, course 5 days.
- A randomized clinical trial using placebo control examined daily vaginal metronidazole for 16 weeks [22]. As a result, 70% of women in the treatment group showed no symptoms of BV, compared with 30% in the placebo group. After treatment ended, relapses occurred in 65% of women in the treatment group at 12 months and in 80% of women in the placebo group. In addition, in patients

- Those who used vaginal cream metronidazole were more likely to have vulvovaginal candidiasis ($p = 0.02$).

- Taking into account the above, it seems relevant to use combination drugs for the treatment of BV, containing, in addition to the antibacterial, also an antimycotic component. One such combination drug is Neo-Penotran, containing 500 mg of metronidazole and 100 mg

- miconazole nitrate in a convenient form in the form of vaginal pessaries, which have virtually no local irritating effect on the vaginal mucosa, ensuring rapid solubility and good acceptability for patients, which distinguishes them favorably from the dosage form - vaginal tablets. Thanks to the combined antibacterial, antiprotozoal and antimycotic action, the presented combination has high clinical

effectiveness. According to various authors [2], the cure rate for BV with the use of Neo-Penotran reaches 96–98%. The drug is prescribed 1 vaginal suppository 2 times a day for 7 days.

Summary. Bacterial vaginosis is now very common and cases of relapse of the disease are observed. This is due to the fact that patients do not complete the full course of treatment together.

with a sexual partner, as well as with reduced immunity or frequent regime changes. sexual partners. Therefore, I believe that the main task required of gynecologists is to give the patient a complete understanding of the treatment procedure and disease prevention. Every attentive woman should undergo medical examinations on time and lead a healthy lifestyle.

LITERATURA

1. Temirova, D. O. (2024). Diagnosis of Cervical Erosion. *American Journal of Bioscience and Clinical Integrity*, 1(11), 84-89.
2. ZHUMAeva, D. (2024). OPTIMIZATION OF METHODS OF DIAGNOSTICS OF VARIOUS FORMS OF ENDOMETRIOSIS IN WOMEN OF REPRODUCTIVE AGE. *Valeology: International Journal of Medical Anthropology and Bioethics* (2995-4924), 2(9), 120-125.
3. Абдукаримов, У. Г., Ихтиярова, Г. А., & Джумаева, Д. Р. (2024). Скрининг Рака Молочной Железы: Настоящее И Будущее. Обзор Литературы. *Research Journal of Trauma and Disability Studies*, 3(2), 144-148.
4. Хикматова, Н. И., & Жумаева, Д. Р. (2023). Инвазивные И Неинвазивные Методы Диагностики Заболевания Молочных Желез. *Central Asian Journal of Medical and Natural Science*, 4(6), 652-658.
5. D.R.Zhumaeva, D.R.Zhumaeva (2024) *The State of the Vaginal Microbiocenosis, Bacterial Vaginosis and its Treatment Options*. American Journal of Bioscience and Clinical Integrity, 1 (11). pp. 78-83. ISSN 2997-7347
6. ERGASHEVA, G. T. (2024). OBESITY AND OVARIAN INSUFFICIENCY. *Valeology: International Journal of Medical Anthropology and Bioethics*, 2(09), 106-111.



7. Ergasheva, G. T. (2024). Modern Methods in the Diagnosis of Autoimmune Thyroiditis. *American Journal of Bioscience and Clinical Integrity*, 1(10), 43-50.
8. Tokhirovna, E. G. (2024). COEXISTENCE OF CARDIOVASCULAR DISEASES IN PATIENTS WITH TYPE 2 DIABETES. *TADQIQOTLAR. UZ*, 40(3), 55-62.
9. Toxirovna, E. G. (2024). DETERMINATION AND STUDY OF GLYCEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH COMORBID DISEASES. *TADQIQOTLAR. UZ*, 40(3), 71-77.
10. Toxirovna, E. G. (2024). XOMILADORLIKDA QANDLI DIABET KELTIRIB CHIQUARUVCHI XAVF OMILLARINI ERTA ANIQLASH USULLARI. *TADQIQOTLAR. UZ*, 40(3), 63-70.
11. Toxirovna, E. G. (2024). QANDLI DIABET 2-TIP VA KOMORBID KASALLIKLARI BO'LGAN BEMORLARDA GLIKEMIK NAZORAT. *TADQIQOTLAR. UZ*, 40(3), 48-54.
12. Tokhirovna, E. G. (2024). MECHANISM OF ACTION OF METFORMIN (BIGUANIDE) IN TYPE 2 DIABETES. *JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH*, 3(5), 210-216.
13. Tokhirovna, E. G. (2024). THE ROLE OF METFORMIN (GLIFORMIN) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 4(4), 171-177.
14. Эргашева, Г. Т. (2024). Эффект Применения Бигуанида При Сахарным Диабетом 2 Типа И Covid-19. *Research Journal of Trauma and Disability Studies*, 3(3), 55-61.
15. Toxirovna, E. G. (2024). QANDLI DIABET 2 TUR VA YURAK QON TOMIR KASALLIKLARINING BEMOLARDA BIRGALIKDA KECISHI. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(7), 202-209.
16. Мухиддинова, Х. С. (2024). РАЗВИТИЕ ЯИЧНИКОВ, ИХ МОРФОЛОГИЯ И ОСОБЕННОСТИ



ФУНКЦИОНИРОВАНИЕ. ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 55(2), 134-141.

17. Мухитдинова, Х. С. (2024). СОВРЕМЕННЫЕ ВЗГЛЯДЫ НА РАЗВИТИЕ БАКТЕРИАЛЬНОГО ВАГИНОЗА У ЖЕНЩИН ФЕРТИЛЬНОГО ВОЗРАСТА. ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 55(2), 97-103.

18. Мухитдинова, Х. С. (2024). ЗАБОЛЕВАЕМОСТЬ СПИДОМ, МОРФОЛОГИЧЕСКИЕ ОСОБЕННОСТИ БОЛЕЗНИ. ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 55(2), 104-112.

19. Samikhovna, M. K. (2024). Clinical and Morphological Aspects of the Functioning of the Lymphatic System. *International Journal of Alternative and Contemporary Therapy*, 2(9), 101-106.

20. Samikhovna, M. K. (2024). MODERN VIEWS ON ACROMEGALY AND IMMUNOMORPHOLOGY OF THIS DISEASE. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 4(10), 179-183.

21. Saloxiddinovna, X. Y. (2024). Modern Views on the Effects of the Use of Cholecalciferol on the General Condition of the Bod. *JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH*, 3(5), 79-85.

22. Халимова, Ю. С., & Хафизова, М. Н. (2024). МОРФО-ФУНКЦИОНАЛЬНЫЕ И КЛИНИЧЕСКИЕ АСПЕКТЫ СТРОЕНИЯ И РАЗВИТИЯ ЯИЧНИКОВ (ОБЗОР ЛИТЕРАТУРЫ). *TADQIQOTLAR. UZ*, 40(5), 188-198.

23. Халимова, Ю. С. (2024). Морфологические Особенности Поражения Печени У Пациентов С Синдромом Мэллори-Вейса. *Journal of Science in Medicine and Life*, 2(6), 166-172.

24. Halimova, Y. S. (2024). Morphology of the Testes in the Detection of Infertility. *Journal of Science in Medicine and Life*, 2(6), 83-88.

25. Халимова, Ю. С., & Хафизова, М. Н. (2024). ОСОБЕННОСТИ СОЗРЕВАНИЕ И ФУНКЦИОНИРОВАНИЕ ЯИЧНИКОВ. ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 55(2), 188-194.



26. Хафизова, М. Н., & Халимова, Ю. С. (2024). МОТИВАЦИОННЫЕ МЕТОДЫ ПРИ ОБУЧЕНИИ ЛАТЫНИ И МЕДИЦИНСКОЙ ТЕРМИНОЛОГИИ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 55(2), 165-171.
27. Хафизова, М. Н., & Халимова, Ю. С. (2024). ИСПОЛЬЗОВАНИЕ ЧАСТОТНЫХ ОТРЕЗКОВ В НАИМЕНОВАНИЯХ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ В ФАРМАЦЕВТИКЕ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 55(2), 172-178.
28. Saloxiddinovna, X. Y., & Ne'matillaevna, X. M. (2024). FEATURES OF THE STRUCTURE OF THE REPRODUCTIVE ORGANS OF THE FEMALE BODY. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 55(2), 179-183.
29. Халимова, Ю. С., & Хафизова, М. Н. (2024). КЛИНИЧЕСКИЕ АСПЕКТЫ ЛИЦ ЗЛОУПОТРЕБЛЯЮЩЕЕСЯ ЭНЕРГЕТИЧЕСКИМИ НАПИТКАМИ. *TADQIQOTLAR. UZ*, 40(5), 199-207.
30. Халимова, Ю. С., & Хафизова, М. Н. (2024). КЛИНИЧЕСКИЕ ОСОБЕННОСТИ ЗАБОЛЕВАНИЙ ВНУТРЕННИХ ОРГАНОВ У ЛИЦ, СТРАДАЮЩИХ АЛКОГОЛЬНОЙ ЗАВИСИМОСТЬЮ. *TADQIQOTLAR. UZ*, 40(5), 240-250.
31. Халимова, Ю. С., & Хафизова, М. Н. (2024). кафедра Клинических наук Азиатский международный университет Бухара, Узбекистан. *Modern education and development*, 10(1), 60-75.
32. Халимова, Ю. С., & Хафизова, М. Н. (2024). МОРФО-ФУНКЦИОНАЛЬНЫЕ И КЛИНИЧЕСКИЕ АСПЕКТЫ ФОРМИРОВАНИЯ КОЖНЫХ ПОКРОВОВ. *Modern education and development*, 10(1), 76-90.
33. Nematilloevna, K. M., & Salokhiddinovna, K. Y. (2024). IMPORTANT FEATURES IN THE FORMATION OF DEGREE OF COMPARISON OF ADJECTIVES IN LATIN. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 55(2), 150-157.



34. KHALIMOVA, Y. S. (2024). MORPHOFUNCTIONAL CHARACTERISTICS OF TESTICULAR AND OVARIAN TISSUES OF ANIMALS IN THE AGE ASPECT. *Valeology: International Journal of Medical Anthropology and Bioethics*, 2(9), 100-105.
35. Salokhiddinovna, K. Y., Saifiloevich, S. B., Barnoevich, K. I., & Hikmatov, A. S. (2024). THE INCIDENCE OF AIDS, THE DEFINITION AND CAUSES OF THE DISEASE. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 55(2), 195-205.
36. Salokhiddinovna, K. Y. (2024). IMMUNOLOGICAL CRITERIA OF REPRODUCTION AND VIABILITY OF FEMALE RAT OFFSPRING UNDER THE INFLUENCE OF ETHANOL. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 4(10), 200-205.
37. Nematilloevna, X. M., & Saloxiddinovna, X. Y. (2024). TIBBIYOT FANLARIDA MOTIVATSIYON METODLAR. *Modern education and development*, 16(7), 31-42.
38. Nematilloevna, X. M., & Saloxiddinovna, X. Y. (2024). TURLI TIBBIY TERMINLARNING YASALISH USULLARI. *Modern education and development*, 16(7), 68-78.
39. Nematilloevna, X. M., & Saloxiddinovna, X. Y. (2024). TIBBIY TERMINOLOGIYADA TARJIMA MASALALARI. *Modern education and development*, 16(7), 43-56.
40. Nematilloevna, X. M., & Saloxiddinovna, X. Y. (2024). TIBBIY TERMINOLOGIYADA TARJIMA MASALALARI. *Modern education and development*, 16(7), 43-56.
41. Nematillaevna, K. M., & Salokhiddinovna, K. Y. (2024). NUMERALS IN THE LATIN. *Modern education and development*, 16(7), 57-67.
42. Khalimova, Y. S. (2024). Features of Sperm Development: Spermatogenesis and Fertilization. *American Journal of Bioscience and Clinical Integrity*, 1(11), 90-98.



43. Sharapova, N. (2023). ARTERIAL GIPERTENZIYA VA SEMIZLIK KASALLIKLARINING O'ZARO BOG'LIQLIK SABABLARI VA METABOLIK SINDROMLAR. *Центральноазиатский журнал образования и инноваций*, 2(11 Part 2), 174-179.
44. Шарапова, Н. (2023). КЕКСА ВА ҚАРИ ЁШЛИ АЁЛЛАРДА БЕЛ АЙЛАНАСИНИНГ ЖИСМОНИЙ ФАОЛЛИК БИЛАН БОҒЛИҚЛИГИ ҚИЁСИЙ ТАҲЛИЛИ. *Центральноазиатский журнал образования и инноваций*, 2(12 Part 2), 127-133.
45. Erkinjonovna, S. N. (2023). DIABETES MELLITUS IN PREGNANT WOMEN. *Best Journal of Innovation in Science, Research and Development*, 110-116.
46. Erkinjonovna, S. N. (2024). CHARACTERISTICS OF DENTAL PROSTHESES WEARING IN PATIENTS WITH TYPE 2 DIABETES ACCORDING TO KIDNEY IMPAIRMENT. *PEDAGOG*, 7(1), 84-88.
47. Erkinjonovna, S. N. (2024). THE BEST WAYS TO CONTROL HIGH BLOOD PRESSURE WITHOUT MEDICATION. *Journal of new century innovations*, 47(2), 175-183.
48. Halimovna, M. M. (2021). The Role of Features of Linguocountrylearning in Teaching English. *Central Asian Journal of Literature, Philosophy and Culture*, 2(10), 64-68.
49. МАХМУРОВА, М. К. (2021, March). GRAMMATICAL CATEGORIES IN GERMAN AND UZBEK. In *E-Conference Globe* (pp. 118-123).
50. Махмурова, М. Х. (2021). МЕТАФОРЛАР НУТҚ ШАКЛИ СИФАТИДА. *МЕЖДУНАРОДНЫЙ ЖУРНАЛ ИСКУССТВО СЛОВА*, 4(1-1).
51. A'zamovna, A. R., Halimovna, M. M., & Bakhtiyorovna, N. M. (2019). The matter of equivalence in English and Uzbek proverbs. *Test Engineering and Management*, 81(11-12), 1632-1637.
52. Makhmurova, M. H. (2024). Applications of the Latin Language in Speech. *American Journal of Alternative Education*, 1(8), 59-63.



53. Махмурова, М. Х. (2024). Теоретико-Литературное Развитие Учащихся При Изучении Басен. *Miasto Przyszłości*, 54, 1032-1035.
54. Махмурова, М. (2021). ЎҚУВЧИ БИЛИШ ФАОЛИЯТИНИ ФАОЛЛАШТИРИШДА ИЖОДИЙ ГРАФИК МАСАЛАЛАРНИ Auto CAD ДАСТУРИ АСОСИДА ЕЧИШ. *ЦЕНТР НАУЧНЫХ ПУБЛИКАЦИЙ (buxdu.uz)*, 3(3).
55. BABAYEVA, V. T., MAKHMUROVA, M. H., & NAZAROVA, G. K. (2021, March). Studying language as the second language learners. In *E-Conference Globe* (pp. 89-94).
56. Salokhiddinovna, X. Y. (2023). Anemia of Chronic Diseases. *Research Journal of Trauma and Disability Studies*, 2(12), 364-372.
57. Salokhiddinovna, X. Y. (2023). MALLORY WEISS SYNDROME IN DIFFUSE LIVER LESIONS. *Journal of Science in Medicine and Life*, 1(4), 11-15.
58. Salohiddinovna, X. Y. (2023). SURUNKALI KASALLIKLARDA UCHRAYDIGAN ANEMIYALAR MORFO-FUNKSIONAL XUSUSIYATLARI. *Ta'lim innovatsiyasi va integratsiyasi*, 10(3), 180-188.
59. Халимова, Ю. С. (2024). КЛИНИКО-МОРФОЛОГИЧЕСКИЕ ОСОБЕННОСТИ ВИТАМИНА D В ФОРМИРОВАНИЕ ПРОТИВОИНФЕКЦИОННОГО ИММУНИТА. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 36(3), 86-94.
60. Saloxiddinovna, X. Y. (2024). CLINICAL FEATURES OF VITAMIN D EFFECTS ON BONE METABOLISM. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 36(5), 90-99.
61. Saloxiddinovna, X. Y. (2024). CLINICAL AND MORPHOLOGICAL ASPECTS OF AUTOIMMUNE THYROIDITIS. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 36(5), 100-108.
62. Saloxiddinovna, X. Y. (2024). MORPHOFUNCTIONAL FEATURES BLOOD MORPHOLOGY IN AGE-RELATED CHANGES. *Лучшие интеллектуальные исследования*, 14(4), 146-158.



63. Saloxiddinova, X. Y. (2024). CLINICAL MORPHOLOGICAL CRITERIA OF LEUKOCYTES. *Лучшие интеллектуальные исследования*, 14(4), 159-167.
64. Saloxiddinova, X. Y. (2024). Current Views of Vitamin D Metabolism in the Body. *Best Journal of Innovation in Science, Research and Development*, 3(3), 235-243.
65. Saloxiddinova, X. Y. (2024). MORPHOFUNCTIONAL FEATURES OF THE STRUCTURE AND DEVELOPMENT OF THE OVARIES. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 4(4), 220-227.